Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · DECIPHER LABS LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
DECIPHER LABS LIMITED
BSE: 524752
BSE: 524752
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
DECIPHER LABS LIMITED
StateQ4 FY26 filed
Last close · 28 Oct 2026₹5.49
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · 0.67 · —
DECIPHER LABS LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 65 | 46 | 36 | 23 | 14 |
| EBITDA (ex other income) | 6 | (11) | (1) | (7) | (3) |
| margin % | 9.2 | (23.4) | (2.7) | (32.0) | (24.1) |
| Owners' profit | 12 | 0 | (2) | (5) | (3) |
| EPS, as reported (₹) | 11.27 | (2.66) | (1.66) | (5.03) | (3.05) |
| ROE % · ROCE % | 49.4 · 41.6 | (4.1) · (15.4) | (7.7) · (4.5) | (22.2) · (27.9) | (37.4) · (44.7) |
| Debt / equity (x) | 0.43 | 0.04 | 0.00 | 0.01 | 0.06 |
| Cash from operations | 8 | (2) | 5 | (10) | (2) |
| Capex | (0) | (1) | (0) | (0) | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · DECIPHER LABS LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 6 | 6 | 4 | 3 | 4 | 3 | 4 |
| Profit before tax | 1 | (1) | (1) | (6) | (3) | 0 | (1) | 0 |
| Net profit | 1 | (1) | (1) | (4) | (3) | 0 | (1) | (0) |
| EPS (₹) | 0.94 | (1.31) | (0.59) | (4.07) | (3.39) | 0.02 | (0.53) | 0.35 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Manufacturing and Trading of Pharmaceutical drugs | 1 | 4.8 |
| Consultancy Services | 13 | 95.2 |
| Total, before eliminations | 14 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 0.7 | 3.1 | 12 of 163 | 93% |
| ROCE | (44.7) | 10.8 | 177 of 183 | 3% |
| ROE | (37.4) | 9.8 | 162 of 166 | 2% |
| Debt / Equity | 0.1 | 0.2 | 70 of 166 | 58% |
| EBITDA margin | 11.1 | 17.5 | 117 of 165 | 29% |
| Revenue growth | 3.0 | 16.3 | 119 of 161 | 26% |
| Profit growth | 91.3 | 30.9 | 38 of 158 | 76% |
| Market cap | 6 | 806 | 179 of 181 | 1% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · DECIPHER LABS LIMITED · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Oct 2026 · Compliance certificate on dematerialized securities for Sep 2026 quarter | compliance | minimal | — | — |
| 30 Sept 2026 · All 5 resolutions passed at Decipher Labs 40th AGM | board shareholder meetings | low | — | — |
| 30 Sept 2026 · 40th AGM: All 5 resolutions passed with 100% approval | board shareholder meetings | low | — | — |
| 29 Sept 2026 · Trading window closure ahead of Q2 and H1 FY27 results | compliance | minimal | — | — |
| 9 Sept 2026 · Newspaper advertisement for 30th AGM on September 30, 2026 | compliance | minimal | — | — |
| 8 Sept 2026 · Book Closure and E-Voting Cut-Off Date for 40th AGM on 30 September 2026 | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Decipher Labs files 40th Annual Report, AGM on Sept 30, 2026 | compliance | low | — | — |
| 8 Sept 2026 · Notice of 40th AGM scheduled for 30 September 2026 via video conferencing | board shareholder meetings | low | — | — |
| 5 Sept 2026 · New statutory auditor appointed, independent director resigns | management changes | medium | — | — |
| 5 Sept 2026 · Board outcome: new statutory auditor appointed, independent director resigns | management changes | medium | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in